EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE | A208452 | MYLAN PHARMACEUTICALS INC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
Janssen Pharmaceutica, N.V. et al v. Mylan Pharmaceuticals, Inc. et al 3 patentsANDA 208452emtricitabine, rilpivirine, and tenofovir disoproxil fumarate | N.D. W. Va. | 2015-09-02 | Terminated 2017-07-06 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$114.99
per ea
Lowest NADAC/Unit
$114.99
per ea
Brand NDCs
0
Generic NDCs
1
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 00378544093EMTRICITABINE-RILPIVIRINE-TENOFOVIR DIS FUM 200-25-300 MG TB | $114.99 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.